Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
D-RVd for frontline myeloma looks robust in GRIFFIN trial update
Key clinical point: The benefit of daratumumab added to lenalidomide, bortezomib, and dexamethasone (D-RVd) for frontline treatment of patients with transplant-eligible multiple myeloma continues to improve with longer follow-up of GRIFFIN trial.
Major finding: The stringent complete response rate with 22.1 months of follow-up was 62.6% for D-RVd, versus 45.4% for RVd.
Study details: Updated results of GRIFFIN, a randomized, phase 2 trial including 207 patients with newly diagnosed, transplant-eligible multiple myeloma.
Disclosures: Dr. Voorhees reported disclosures related to Takeda, Oncopeptides, Novartis, GSK, Janssen, Celgene, BMS, Adaptive Biotechnologies, Amgen, and TeneBio.
Voorhees PM et al. ASH 2019, Abstract 691.